Importantly, the pharmacology of spautin-1 extends beyond USP10 inhibition, which might contribute to its anti-obesity efficacy and yield outcomes that do not fully mirror the tissue-selective USP10 suppression. The gene discussed is USP10; the disease is obesity due to melanocortin 4 receptor deficiency.